ENGERIX-B ADULT Rx
Generic Name and Formulations:
Hepatitis B vaccine (recombinant) 20mcg/mL; aluminum hydroxide adsorbed; IM inj; preservative-free; contains thimerosal (trace).
Indications for ENGERIX-B ADULT:
Hepatitis B immunization.
Give IM in deltoid muscle. 11–19yrs: 10mcg at elected date and repeat 1 and 6 months later, or 20mcg at elected date and repeat 1, 2, and 12 months later, or 20mcg at elected date and repeat 1 and 6 months later. >19yrs: 20mcg at elected date and repeat 1 and 6 months later, or 20mcg at elected date and repeat 1, 2, and 12 months later. Hemodialysis: 40mcg at elected date and repeat 1, 2, and 6 months later. High-risk: consider hepatitis B immune globulin also. Booster dose: when appropriate, may use 20mcg for persons 11yrs of age and older; hemodialysis patients booster dose is 40mcg.
Give IM in anterolateral thigh or deltoid; see literature. Infants (mothers are HBsAG negative): 10mcg at birth and repeat 1 and 6 months later; infants (mothers are HBsAG positive) and children through age 10yrs: 10mcg at elected date and repeat 1 and 6 months later, or 10mcg at elected date and repeat 1, 2, and 12 months later. High risk: consider hepatitis B immune globulin also. Booster doses: when appropriate, may use 10mcg for children age 10yrs or younger, or 20mcg for ages 11yrs and older.
May defer in acute febrile illness or active infection. May be given SC only if risk of hemorrhage. Have epinephrine inj available. Multiple sclerosis. Pregnancy (Cat.C). Nursing mothers.
Local reactions, malaise, nausea, diarrhea, rash. Anaphylaxis.
Pediatric/Adolescent (single-dose prefilled Tip-Lok syringe)—5 (without needles); Pediatric/Adolescent (single-dose vials)—1, 10; Adult (single-dose prefilled Tip-Lok syringe)—5 (without needles); Adult (single-dose vials)—1, 10, 25
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking